Patients with psoriasis who had comorbidities were associated with worse health-related quality of life and impaired treatment outcomes with conventional therapy, whereas biologic treatments maintained high efficacy despite presence of co-occuring conditions.
Presence of comorbidities may exacerbate skin lesion severity and reduce the efficacy of conventional therapy in patients with psoriasis, according to study findings published in International Journal of Environmental Research and Public Health.
Associated with a higher prevalence of comorbidities than the general population, patients with psoriasis have been linked with cardiovascular diseases and metabolic disorders, including diabetes, overweight/obesity, and lipid disturbances. Moreover, the impact of psoriasis has been shown to have an extensive impact on the health-related quality of life (HRQOL) of patients.
“Apart from its debilitating effect on the patient’s physical health, psoriasis disturbs the patient’s mental well-being, interferes with their daily routines and work activities, as well as social and family relationships,” noted researchers. “Undoubtedly, smoking exacerbates the course of psoriasis, has a negative effect on the outcome of treatment, and it is conducive to serious complications.”
They investigated the impact of comorbidities (hypertension, diabetes, lipid disorders), overweight/obesity (body mass index [BMI] score), and smoking status on HRQOL, measured by the Dermatology Life Quality Index (DLQI), prior to (baseline visit) and after a 3-month treatment course (control visit).
The analysis of 184 adult patients with plaque psoriasis (mean [SD] age, 46 [12] years) also examined psoriasis severity, measured via Psoriasis Area Severity Index (PASI), in which various types of systemic treatment, both conventional (methotrexate, cyclosporine, retinoids) and biological (adalimumab, ustekinumab, and secukinumab), were examined regarding median DLQI or PASI reduction from baseline.
In their findings, patients with psoriasis who had comorbidities presented with worse HRQOL and more severe skin lesions. At baseline, presence of comorbidities, BMI greater than or equal to 25 kg/m2, and smoking was associated with significantly higher DLQI and PASI scores vs patients without comorbidities, those whose BMI was below 25 kg/m2, and non-smokers.
After 3-month treatment, significant differences were still observed in the median PASI and DLQI scores between the studied subjects with comorbidities, BMI greater than or equal to 25 kg/m2, and smokers vs those presenting with no comorbidities, BMI below 25 kg/m2, and non-smokers, but these scores were lower in comparison with scores observed before treatment.
Regarding the impact of comorbidities on treatment efficacy, presence of comorbidities had a negative effect on the outcome of treatment with the use of conventional therapy, whereas methotrexate was effective even if the patients had co-existing hypertension.
Use of biologic therapies conversely exhibited high effectiveness in improving psoriatic skin lesions regardless of the presence of comorbidities. Although, the outcome of therapy with biological agents was independent of each of the analyzed factors (smoking, overweight/obesity).
“In patients with psoriasis receiving systemic conventional treatment, but not biological treatment, comorbidities had a negative impact on HRQOL and psoriasis severity,” concluded researchers.
Reference
Karpinska-Mirecka A, Bartosinska J, Krasowska D. The impact of hypertension, diabetes, lipid disorders, opverweight/obesity and nicotine dependence on health-related quality of life and psoriasis severity in psoriatic patients receiving systemic conventional and biological treatment. Int J Environ Res Public Health. Published online December 14, 2021. doi:10.3390/ijerph182413167
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Goal Achievement in T1D Management Boosts Self-Efficacy, Self-Care Among Emerging Adults
May 9th 2024Findings from the FAMS-T1D study demonstrate that structured goal-setting and achievement significantly enhance self-efficacy and self-care in emerging adults who have type 1 diabetes (T1D).
Read More
Medication Adherence Star Ratings Measures, Health Care Resource Utilization, and Cost
May 9th 2024For patients prescribed diabetes, hypertension, and hyperlipidemia medications, nonadherence to CMS Star Ratings quality measures of medication adherence was associated with increased health care resource utilization and costs.
Read More